Paroxetine

Generic Name: Paroxetine

Brand Names: Paxil, Pexeva

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀FNO_₃

CAS Number: 61869-08-7

Unique Ingredient Identifier: 41VRH5220H

Background: Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...

Indication: Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...

Associated Conditions: Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments

Phase 4

Completed

Conditions: Postmenopausal Flushing
Endothelial Dysfunction
Cardiovascular Risk Factor

Interventions: Drug: Placebo oral capsule
Drug: Paroxetine

First Posted Date: 2017-05-11

Last Posted Date: 2018-04-12

Lead Sponsor: Rio de Janeiro State University

Target Recruit Count: 140

Registration Number: NCT03149419

Locations: 🇧🇷
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vortioxetine
Drug: Paroxetine
Drug: Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 361

Registration Number: NCT02932904

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine

Phase 4

Completed

Conditions: Agoraphobia
Panic Disorder

Interventions: Drug: Clonazepam
Drug: Paroxetine

First Posted Date: 2016-08-02

Last Posted Date: 2016-08-02

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 120

Registration Number: NCT02852577

Locations: 🇧🇷
Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lofexidine
Drug: Paroxetine

First Posted Date: 2016-02-12

Last Posted Date: 2018-02-23

Lead Sponsor: USWM, LLC (dba US WorldMeds)

Target Recruit Count: 24

Registration Number: NCT02681198

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

First Posted Date: 2016-01-14

Last Posted Date: 2021-07-02

Lead Sponsor: University of Washington

Target Recruit Count: 635

Registration Number: NCT02655354

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Honor Health, Scottsdale, Arizona, United States

and more 21 locations

Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome

Phase 1

Completed

Conditions: Fibromyalgia

Interventions: Drug: Venlafaxine
Drug: Paroxetine
Drug: Amitriptyline

First Posted Date: 2015-05-22

Last Posted Date: 2015-05-22

Lead Sponsor: Mansoura University

Target Recruit Count: 75

Registration Number: NCT02451475

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Completed

Conditions: Acute Kidney Injury
Depression

Interventions: Drug: Duloxetine
Drug: Citalopram
Drug: Escitalopram
Drug: Venlafaxine
Drug: Desvenlafaxine
Drug: Fluoxetine
Drug: Fluvoxamine
Drug: Paroxetine
Drug: Sertraline

First Posted Date: 2014-12-19

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 3255526

Registration Number: NCT02320240

Locations: 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder

Phase 4

Conditions: Major Depression Disorder

Interventions: Drug: Buspirone
Drug: Paroxetine

First Posted Date: 2014-10-23

Last Posted Date: 2014-10-23

Lead Sponsor: Si Tianmei

Target Recruit Count: 240

Registration Number: NCT02273154

Locations: 🇨🇳
Henan mental health center, Xinxiang, Henan, China
🇨🇳
Institute of mental health, Peking University, Beijing, Beijing, China
🇨🇳
Wuhan mental health center, Wuhan, Hubei, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy